Losartan and diabetic nephropathy: commentaries on the RENAAL study

The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study is a multinational, double-blind, randomized, placebo controlled trial which was recently published. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in patients with diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisman, Enrique Z, Tenenbaum, Alexander, Motro, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC116616/
https://www.ncbi.nlm.nih.gov/pubmed/12119058
http://dx.doi.org/10.1186/1475-2840-1-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC116616/
https://www.ncbi.nlm.nih.gov/pubmed/12119058
http://dx.doi.org/10.1186/1475-2840-1-2

Ejemplares similares